Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.

Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.

Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.

Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.

Agner Paner, MD, will address updates in supportive care for patients with multiple myeloma at the virtual 2020 Great Debates & Updates in Hematologic Malignancies.

Ajai Chari, MD, discusses the phase 1b PAVO study, which evaluated the safety of faster corticosteroid tapering in patients with relapsed/refractory MM receiving subcutaneous daratumumab.

Keith Stewart, MD, ChB, discusses therapeutic approaches for patients with early relapse of MM.

Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.